SCHEMBL2860183

SCHEMBL2860183

Nc1c2c(=O)[nH]c3ccccc3c2nn1-c1cc(O)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.46
SRC P12931 3/20 0.46
FGFR2 P21802 3/20 0.46
FGFR4 P22455 3/20 0.46
FGFR3 P22607 3/20 0.46
KDR P35968 3/20 0.46
ADORA3 P0DMS8 3/20 0.46
TDP2 O95551 1/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
CASP6 P55212 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CHEK1 O14757 1/20 0.38
PDE2A O00408 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
DAO P14920 1/20 0.37
PTGES O14684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2871518 0.89 PDE2A (0.47) ADORA3CHEK1PDE2AKDM4EHTT
SCHEMBL2857583 0.87 ADORA3 (0.43) FGFR1KDRADORA3TDP2MEN1
SCHEMBL2861307 0.87 ADORA3 (0.43) ADORA3TDP2MEN1POLBGAA
SCHEMBL2870546 0.84 PDE2A (0.47) ADORA3MEN1KMT2APDE2AKDM4E
SCHEMBL2864291 0.83 PDE2A (0.42) FGFR1ADORA3GAACHEK1PDE2A
SCHEMBL2866719 0.82 PDE2A (0.43) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL2877778 0.82 TDP2 (0.49) SRCADORA3TDP2MEN1POLB
SCHEMBL2881305 0.82 KDM4E (0.43) SRCADORA3TDP2MEN1POLB
SCHEMBL2878474 0.81 TDP2 (0.49) SRCADORA3TDP2MEN1GAA
SCHEMBL2859234 0.80 ALOX12 (0.52) ADORA3MEN1KMT2ACHEK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US claimed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP claimed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 FGFR1 201/4885SRC 122/4885FGFR2 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.